Ignite Creation Date:
2024-05-06 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03216928
Status:
COMPLETED
Last Update Posted:
2022-07-29
First Post:
2017-06-12
Brief Title:
A New Mode of Action of Anti-TNF Reverse Signaling in Rheumatoid Arthritis
Sponsor:
University Hospital Toulouse
Organization:
University Hospital Toulouse
Study Overview
Official Title:
Pilot Study Investigating a New Mode of Action of Anti-TNF Reverse Signaling in Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TNF-RS-PR
Brief Summary:
Blood test in Rheumatoid Arthritis RA patients with good response to anti-Tumor Necrosis Factor anti-TNF and in patients with moderate or non-response will be done in the month following the evaluation of clinical response to therapy Isolation of mononuclear cells and purification of monocyte by negative selection Cell culture of monocyte in presence or not of anti-TNF for 24 hours and analyze of CD36 cluster of differentiation antigen 36 expression principal outcome For secondary outcomes analyze monocyte phenotype NRF2 nuclear translocation and clinical data of patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None